DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

Information source: Therapeutic Advances in Childhood Leukemia Consortium
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Minimal Residual Disease; Leukemia, Lymphoblastic, Acute; Leukemia, Myelogenous, Acute

Intervention: Clofarabine (Drug); Cytarabine (Drug); Methotrexate (Drug); Cytarabine (Drug)

Phase: Phase 2

Status: Terminated

Sponsored by: Therapeutic Advances in Childhood Leukemia Consortium

Official(s) and/or principal investigator(s):
Blythe Thomson, MD, Study Chair, Affiliation: Seattle Children's Hospital

Summary

This study will test the ability of clofarabine + cytarabine to eliminate minimal residual disease (MRD) in acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) patients whose bone marrows exhibit complete remission by morphology. The toxicity profile of this regimen will be evaluated in addition to toxicity experienced by patients who proceed to stem cell transplant. Overall length of remission will also be collected.

Clinical Details

Official title: Clofarabine With Cytarabine for MRD Positive Leukemia

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Ability of clofarabine and cytarabine to eliminate minimal residual disease (MRD) in acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) patients whose bone marrows exhibit complete remission by morphology.

Secondary outcome:

To describe the toxicity profile with this treatment

To describe the toxicity profile during hematopoietic cell transplant (HCT) for patients who achieve remission and proceed to transplant.

To determine the duration of complete remission after this treatment to minimize minimal residual disease.

Detailed description: Recent studies have demonstrated that even low levels of minimum residual disease (MRD) (>0. 01% abnormal blasts) after aggressive re-induction therapy indicate a relatively poor outcome in relapsed acute lymphoblastic leukemia (ALL) patients, including those who proceed to allogeneic stem cell transplant (alloSCT). A similarly poor prognosis was seen in pediatric acute myelogenous leukemia patients with sub-morphologic disease prior to alloSCT. Studies to identify therapies that can eliminate persistent leukemia, have low toxicity profiles and can serve as a bridge to transplant are needed. This study will test the ability of clofarabine + cytarabine to eliminate minimal residual disease (MRD) in acute myelogenous leukemia and acute lymphoblastic leukemia patients whose bone marrows exhibit complete remission by morphology. The toxicity profile of this regimen will be evaluated in addition to toxicity experienced by patients who proceed to stem cell transplant. Overall length of remission will also be collected.

Eligibility

Minimum age: 1 Year. Maximum age: 21 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: Patients must meet all of the following criteria to be eligible to participate in the study. Patients must be ≥1 and ≤ 21 years of age when enrolled onto this study.

- Diagnosis (Patient must have all of the following)

- Patients must have a diagnosis of relapsed acute myelogenous leukemia (AML) or

acute lymphoblastic leukemia (ALL)

- Patient must have an M1 marrow based upon a recovered marrow with less than 5%

blasts by conventional morphology

- Patient must have minimal residual disease (MRD) detected by either

multidimensional or conventional flow cytometry greater than 0. 1% and less than 5% following any re-induction attempt

- Patients must have a central nervous system (CNS) disease status of 1

- Patient must have an absolute neutrophil count (ANC) >500/μL off cytokine support for

at least 24 hours and platelets >50,000 K/μL without platelet transfusion in the past seven days

- Karnofsky > 50% for patients > 10 years of age and Lansky > 50% for patients ≤ 10

years of age.

- Patient must have adequate venous access.

- Patients must have fully recovered from the acute toxic effects of all prior

chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

- At least 21 days must have elapsed from prior chemotherapy, at least 7 days must have

elapsed since receiving biological therapy.

- It must be at least 90 days from any higher dose cytarabine therapy (>1 gm/ m2/day).

- Patients must have a normal calculated creatinine clearance

- Patient must have

1. Conjugated (direct) serum bilirubin ≤ 1. 5 x upper limit of normal (ULN) for age. 2. Alanine transaminase (ALT) ≤ 2. 5 × ULN for age. 3. Alkaline phosphatase ≤ 2. 5 × ULN for age. 4. Serum amylase ≤ 1. 5 ULN for age. 5. Serum Lipase is ≤ ULN for age.

- Patient must have a shortening fraction > 28% or an ejection fraction > 50%.

- Female patients of childbearing potential must have a negative urine or serum

pregnancy test confirmed prior to enrollment.

- Female patients with infants must agree not to breastfeed their infants while on this

study.

- Male and female patients of child-bearing potential must agree to use an effective

method of contraception approved by the investigator during the study.

- Patient must agree to submission of blood and bone marrow for assessment of minimal

residual disease (MRD).

- All patients and/or their parents or legal guardians must sign a written informed

consent. Exclusion Criteria: Patients who meet any of the following criteria will be excluded from participating in the study.

- Patients with previous hematopoietic stem cell transplant (HSCT) within previous six

months.

- Patients who have had prior treatment with clofarabine.

- Patients with CNS2 or CNS 3 disease or bulky chloromatous disease.

- Patients with Down Syndrome.

- Patients with a previous history of veno-occlusive disease (VOD) or findings

consistent with a diagnosis of VOD.

- Patients with a systemic fungal, bacterial, viral, or other infection not controlled.

- Use of investigational agents within 30 days of planned treatment on this protocol.

- Patient is receiving or plans to receive concomitant chemotherapy, radiation therapy,

immunotherapy or other anti-cancer therapy other than is specified in the protocol.

- Pregnant or lactating patients.

- Any significant concurrent disease, illness, psychiatric disorder or social issue

that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.

- Have had a diagnosis of another malignancy, unless the patient has been disease-free

for at least 3 years following the completion of curative intent therapy with the following exceptions: 1. Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intra-epithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed. 2. Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate-specific antigen (PSA) values are also eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed.

Locations and Contacts

Alberta Children's Hospital, Calgary, Canada

British Columbia Children's Hospital, Vancouver, Canada

Phoenix Children's Hospital, Phoenix, Arizona, United States

City of Hope, Duarte, California 91010, United States

Miller Children's Hospital, Long Beach, California, United States

Childrens Hospital Los Angeles, Los Angeles, California 90027, United States

Oakland Children's Hospital, Oakland, California, United States

Stanford University Medical Center, Palo Alto, California 94304-1812, United States

UCSF School of Medicine, San Francisco, California 94143-0106, United States

University of Miami Cancer Center, Miami, Florida 33136, United States

Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, United States

Children's Memorial, Chicago, Illinois, United States

Johns Hopkins University, Baltimore, Maryland, United States

Dana Farber, Boston, Massachusetts, United States

C.S. Mott Children's Hospital, Ann Arbor, Michigan 48109-0914, United States

Childrens Hospital & Clinics of Minnesota, Minneapolis, Minnesota 55404-4597, United States

University of Minnesota Children's Hospital, Minneapolis, Minnesota, United States

Children's Hospital New York-Presbyterian, New York, New York 10032, United States

New York University Medical Center, New York, New York 10016, United States

Nationwide Childrens Hospital, Columbus, Ohio, United States

Hospital for Sick Kids, Toronto, Ontario, Canada

Oregon Health and Science University, Portland, Oregon, United States

St. Jude, Memphis, Tennessee 38105-3678, United States

Vanderbilt Children's Hospital, Nashville, Tennessee, United States

Seattle Children's Hospital, Seattle, Washington 98105, United States

Additional Information

Starting date: August 2010
Last updated: October 24, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017